Galderma's Nemluvio Shows Sustained Benefits In Inflammatory Skin Diseases Through 3 Years
(RTTNews) - Thursday, Galderma (GALD.SW) presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis (AD).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.